1. ALLA AKTIER
  2. NYHETER
  3. BONESUPPORT

Bonesupport

Nyheter Bonesupport Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

Announced Insider Trading


Emil Billbäck, CEO, has sold 172,600 shares for personal financial reasons. After the transaction, he owns 363,571 shares.

Dr. Michael Diefenbeck, Chief Medical Officer and EVP Clinical Affairs, has sold 18,000 shares to cover tax effects and pay the exercise price for the employee 2016 stock options program. After the transaction, he owns 84,160 shares.

For more information contact:

BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 591 million in 2023. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Attachments

Announced Insider Trading

Datum 2024-10-28, kl 10:00
Källa MFN
Bifogade filer
Announced Insider Trading